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Abstract Oral fluoropyrimidine anticancer agents (oral
5-fluorouracil [5-FU]) able to be used as chemotherapy for
breast cancer include tegafur–uracil (UFT), tegafur–
gimeracil–oteracil potassium (S-1), doxifluridine, and
capecitabine. Since the 1980s, UFT has been most widely
used for postoperative chemotherapy in breast cancer. UFT
is an oral preparation that was designed to achieve and
maintain high concentrations of 5-FU in plasma by com-
bining tegafur, a prodrug of 5-FU, with uracil. UFT is
characterized by mild adverse events, allowing long-term
treatment. The prolonged maintenance of high plasma 5-FU
concentrations has been suggested to inhibit micrometas-
tases after surgery. Recently, large clinical trials conducted
in Japan have shown that UFT-based postoperative che-
motherapy is therapeutically useful in patients with node-
negative (n0), high-risk breast cancer. We review the results
of clinical trials of postoperative chemotherapy with UFT in
Japan and discuss its roles and future prospects.
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Introduction
In their guidelines for treatment selection according to risk
category, the St. Gallen International Conference recom-
mend endocrine therapy alone or chemotherapy followed
by endocrine therapy for postoperative adjuvant chemo-
therapy in patients with estrogen receptor (ER)-positive,
human epidermal growth factor receptor 2 (HER2)-nega-
tive breast cancer [1]. The National Comprehensive Cancer
Network (NCCN) guidelines also recommend similar
treatment options. However, among patients with ER-
positive, HER2-negative breast cancer, it remains to be
clarified which chemotherapeutic regimens are most
effective in what types of patients.
At present, combinations of drugs such as anthracyclines
and taxanes are used as standard postoperative chemo-
therapy in patients with breast cancer. However, recent
studies have suggested that these standard chemothera-
peutic regimens provide limited therapeutic effectiveness
in patients with ER-positive or HER2-negative breast
cancer. Awareness that conventional standard anticancer
agents are not necessarily adequate for the management of
ER-positive, HER2-negative breast cancer has led to the
search for new treatment strategies.
Fluoropyrimidine derivatives used as chemotherapy
for breast cancer
In 1956, 5-fluorouracil (5-FU), a fluoropyrimidine, was
synthesized by Heidelberger et al. and Duschinsky et al.
This drug continues to play a central role in chemotherapy
of solid tumors and is an important component of combi-
nation chemotherapy regimens for breast cancer. In breast
cancer, 5-FU is mainly given as a bolus injection in regi-
mens such as cyclophosphamide, methotrexate, and 5-FU
(CMF) and 5-FU, epirubicin, and cyclophosphamide
(FEC). Experimental studies have suggested that divided,
low doses of 5-FU have a greater impact on survival than a
large single bolus dose [2].
However, 5-FU has the disadvantage that 85 % of the
administered dose is promptly catabolized and inactivated
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by dihydropyrimidine dehydrogenase (DPD), similar to
uracil. Derivatives of 5-FU have been developed to
overcome this disadvantage and to enhance antitumor
efficacy.
Tegafur, a prodrug of 5-FU, was synthesized in 1967 for
injectable use. Subsequently, tegafur was found to be well
absorbed after oral administration, resulting in prolonged
plasma concentrations of tegafur and 5-FU. These findings
led to the development of oral formulations (Fig. 1).
Oral 5-FU preparations developed in Japan were
approved on the basis of the results of clinical trials in
women with metastatic or recurrent breast cancer. After
entering the 1990s, oral formulations of 5-FU have been
widely used as postoperative chemotherapy for breast
cancer because of convenience of administration and low
incidences of serious adverse events. At that time, however,
the Adjuvant Chemoendocrine Therapy for Breast Cancer
(ACETBC) trial was in progress to confirm the effective-
ness of UFT as postoperative chemotherapy for breast
cancer, and this drug had been used in general clinical
practice without adequate clinical evidence of efficacy.
Moreover, CMF, an internationally accepted standard
therapy, was not used in Japan at that time. Therefore, the
National Surgical Adjuvant Study of Breast Cancer 01
(NSAS-BC01) trial was started as a clinical research pro-
ject supported by the Japanese Ministry of Health, Labor,
and Welfare to compare UFT with CMF. Around the same
time as this trial, the Study Group for the Comparative Trial
with UFT ? Tamoxifen and CMF ? Tamoxifen in Adju-
vant-therapy for Breast Cancer (CUBC) trial [3–7] was also
started to compare UFT with CMF.
We review the results of clinical trials of UFT per-
formed in Japan and discuss its roles and future prospects.
Postoperative chemotherapy with UFT in breast cancer
UFT is a preparation combining tegafur, a prodrug of
5-FU, with uracil. However, after tegafur is metabolically
converted into 5-FU, 5-FU is promptly catabolized by DPD
in the liver, similarly to injected 5-FU. Therefore, uracil, a
competitive inhibitor of DPD, was combined with tegafur
to find ways to increase plasma 5-FU concentrations and
enhance antitumor activity. The optimal combination ratio
of tegafur to uracil was found to be 1:4 (molar ratio), taking
into account the balance between efficacy and safety. This
molar ratio was applied to UFT. In addition, metabolites of
tegafur such as c-hydroxybutylate (GHB) and c-butyro-
lactone (GBL) have been reported to inhibit angiogenesis.
Treatment with UFT is thus thought to have 5-FU-induced
cytocidal effects on cancer cells remaining after surgery as
well as inhibitory effects on angiogenesis, produced by
GHB and GBL [8, 9].
In Japan, clinical trials have been conducted to evaluate
postoperative chemotherapy with oral 5-FU preparations in
patients with early breast cancer. In the third ACETBC
trial, which studied the effect of UFT in patients with stage
I–IIIa resected breast cancer, additional treatment with
UFT was shown to improve the 5-year relapse-free survival
rate [hazard ratio of the UFT group to the control group,
0.77; 95 % confidence interval (CI), 0.60–0.99]. In the
fourth ACETBC trial, patients with axillary node-negative
breast cancer were randomly assigned to 4 treatment
groups: surgery alone, postoperative treatment with
tamoxifen for 2 years, postoperative treatment with UFT
for 2 years, and postoperative treatment with tamoxifen
plus UFT for 2 years. An analysis of outcomes according
to the presence or absence of treatment with UFT showed
that UFT significantly improved survival rates. In partic-
ular, among patients with ER-positive breast cancer, the
survival rate was highest in the tamoxifen plus UFT group
(hazard ratio of the tamoxifen plus UFT group to the sur-
gery alone group, 0.28; 95 % CI 0.085–0.93).
Histopathological specimens were retrieved from the
surgical-pathology files for premenopausal women with
ER-positive, axillary-node-positive breast cancer who were
enrolled in the third ACETBC trial (tamoxifen vs. tamox-
ifen plus UFT). The tumor specimens were stained
immunohistochemically to investigate the relation between
HER2 expression status and the inhibitory effect of UFT on
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recurrence. The results suggested that the additive effect
obtained by combining UFT with tamoxifen was unaf-
fected by HER2 expression status [10]. UFT is therefore
expected to inhibit recurrence even in patients with HER2-
negative breast cancer.
Evidence on oral fluoropyrimidine preparations
as compared with CMF control therapy
NSAS-BC01 trial
CMF therapy in Japan is far behind that in Western
countries, and was approved in 1996. After approval,
nationwide clinical trials with a CMF control group were
performed in Japan. One of these studies examined the
noninferiority of UFT to CMF.
The NSAS-BC01 trial was designed to establish the
noninferiority of UFT to CMF in patients with node-
negative (n0), high-risk breast cancer. The primary end-
point was relapse-free survival. Six cycles of classic CMF,
given to the control group, were compared with 2 years of
treatment with UFT. Patients whose tumors were positive
for ER, progesterone receptor, or both concurrently
received tamoxifen (20 mg/day) for 5 years. A total of 733
patients were enrolled in both groups combined. The haz-
ard ratio of the UFT group to the CMF group was 0.98
(95 % CI 0.66–1.45). In patients with n0 high-risk breast
cancer, the noninferiority of the UFT group to the CMF
group was not demonstrated statistically, but the relapse-
free survival curves and survival curves appear to be
superimposable, strongly suggesting that both treatments
are similarly effective [5] (Fig. 2). Grade 3 or 4 adverse
events occurred in fewer than 10 % of the patients in both
arms. The incidence of grade 3 or 4 leucopenia was sig-
nificantly higher in the CMF arm, and the incidences of
grade 3 or 4 diarrhea, anemia, elevated AST, and elevated
serum total bilirubin were significantly higher in the UFT
arm. The incidence of alopecia (any grade) was lower in
the UFT group (9.7 %) than in the CMF group (55.2 %).
CUBC trial
The CUBC trial was designed to demonstrate the nonin-
feriority of UFT to CMF in patients with stage I–IIIa breast
cancer who had 1–9 metastatic axillary nodes. It was per-
formed at the same time as the NSAS-BC01 trial. The
CUBC trial compared 6 cycles of CMF plus 2 years of
tamoxifen with UFT plus tamoxifen, given concurrently for
2 years. On analysis of data on 377 enrolled patients, the
5-year relapse-free survival rate was similar in the CMF
group (76.3 %) and the UFT group (72.3 %). Adverse
events were reported in 88.1 % (156 out of 177) of patients
receiving UFT and in 98.8 % (171 out of 173) of those
receiving CMF, showing a significantly lower incidence in
the UFT group (P = 0.05). The incidence of leukopenia as
well as hemoglobin, anorexia, nausea/vomiting, stomatitis,
and alopecia was significantly higher in the CMF group,
whereas that of liver dysfunction was significantly higher
in the UFT group. A subset analysis according to hormone-
receptor status showed that the 5-year relapse-free survival
rate was better in the CMF group than in the UFT group
among patients with ER-negative tumors. Among patients
with ER-positive tumors, however, the 5-year relapse-free
survival rate was better in the UFT group (81 %) than in
the CMF group (76 %) (hazard ratio of the UFT group to
the CMF group, 0.73; 95 % CI 0.38–1.39). These findings
indicated a trend toward an interaction between ER-
receptor status and therapeutic effectiveness [7].
Oral 5-FU is known to be associated with few adverse
events such as gastrointestinal symptoms, myelosuppres-
sion, and hair loss. Clinical studies performed to date have
Fig. 2 Relapse-free survival
(RFS) and overall survival (OS)
in the NSAS-BC01 trial. a RFS
and b OS of the total patients
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shown a similar trend for UFT. The NSAS-BC01 trial used
the European Organization for Research and Treatment of
Cancer (EORTC) QLQ C30, QLQ-BR23, and the Func-
tional Assessment of Cancer Therapy-Breast (FACT-B)
questionnaires to evaluate patients’ quality of life (QOL).
The results of QOL analyses showed that QOL was dis-
tinctly better in the UFT group than in the CMF group for
about 6 months after the start of treatment. After the
completion of CMF therapy, QOL improved, but was
similar to that in the UFT group. These findings indicated
that a good QOL was maintained during treatment with
UFT (Fig. 3).
Meta-analysis of the NSAS-BC01 and the CUBC trials
The results of a pooled analysis of the NSAS-BC01 trial
and the CUBC trial, both of which compared UFT with
CMF, have been reported [11]. The noninferiority of UFT to
CMF was not demonstrated statistically in the study group
as a whole. In patients with ER-positive tumors, however,
the noninferiority of UFT to CMF was statistically proven
(hazard ratio of the UFT group to the CMF group, 0.79;
97.5 % CI 0.49–1.27). A subgroup analysis showed UFT
was particularly more effective than CMF in patients
50 years or older who had ER-positive tumors (hazard ratio
of the UFT group to the CMF group, 0.58; 95 % CI
0.34–1.01). These results suggested that UFT combined
with endocrine therapy can effectively inhibit recurrence in
patients with ER-positive breast cancer (Fig. 4).
Expectations for S-1
S-1 is a preparation that was developed to achieve higher
antitumor activity than UFT with less toxicity. To reach
this goal, potent DPD inhibitors and agents designed to
reduce adverse events were studied. Gimeracil, a potent
DPD inhibitor about 200-fold more active than uracil, was
developed [12]. To reduce gastrointestinal toxicity, oteracil
potassium was discovered. This drug inhibits activation of
5-FU in the gastrointestinal tract, reducing gastrointestinal
toxicity. To achieve a good balance between efficacy and
toxicity, optimal ratios for combining these 2 components
with tegafur, a prodrug of 5-FU, were studied. Conse-
quently, tegafur, gimeracil, and oteracil potassium were
combined at a molar ratio of 1:0.4:1 in S-1.
As for clinical outcomes in breast cancer, the results of 3
clinical studies of S-1 in patients with advanced or recur-
rent breast cancer have been reported. Response rates were
40.7 and 42.0 % in patients who received S-1 as first- or
second-line treatment, respectively [13], as compared with
21.8 % in patients who did not respond to anthracycline or
taxanes. When UFT was given as first-line treatment, the
response rate was 32 % in patients with advanced or
recurrent breast cancer. The response rate with UFT plus
leucovorin calcium has been reported to range from 10 to
13.2 % in patients who did not respond to anthracyclines or
taxanes. S-1 can be expected to have higher antitumor
activity than UFT [14–16].
At present, the Post Operative Therapy with Endocrine
and TS-1 (POTENT) trial, a randomized, controlled, phase
Fig. 3 Impact of UFT or CMF
on QOL in patients taking part
in the NSAS-BC 01 trial.
European Organization for
Research and Treatment of
Cancer Quality of Life
Questionnaire Core 30 Breast
23 scores for social functioning
(a), nausea and vomiting (b),
and upset by hair loss (c). In the
graph for social functioning, a
higher score indicates better
QOL, whereas for nausea and
vomiting and upset by hair loss,
lower scores indicate better
QOL. d FACT-TOI. A higher
score indicates better QOL.
Data are presented as mean
standard error
Breast Cancer (2013) 20:302–309 305
123
III study of postoperative chemotherapy in patients with
ER-positive, HER2-negative breast cancer, is ongoing.
Discussion
With recent progress in drug therapy, the primary treatment
of early breast cancer has shifted from surgery to multi-
disciplinary treatment, including drug therapy. During the
approximately 30 years since CMF was reported to be
therapeutically useful for postoperative chemotherapy,
many randomized, controlled clinical trials and meta-
analyses of their results have dramatically changed the
management of breast cancer, especially postoperative
chemotherapy. In 1996, classic CMF, designated as stan-
dard therapy in Western countries, was approved in Japan.
Randomized, controlled clinical trials comparing the oral
5-FU preparation UFT with classic CMF therapy were
planned and conducted, leading to the introduction of
standard therapy used in Western countries to Japan.
At present, anthracycline- and taxane-based combina-
tion regimens are mainly used as standard chemotherapy
for the postoperative management of breast cancer. How-
ever, recent studies suggest that standard chemotherapy
with anthracyclines and taxanes is less effective in patients
with ER-positive or HER2-negative breast cancer. A meta-
analysis of 8 studies (5,354 patients) evaluating the efficacy
of postoperative adjuvant therapy with anthracycline
derivatives according to HER2 expression status suggested
that anthracyclines are only marginally beneficial in
patients with HER2-negative tumors [17]. A subset anal-
ysis of the Cancer and Leukemia Group B (CALGB) 9344
trial, which evaluated the additive effect of paclitaxel after
doxorubicin (Adriamycin) plus cyclophosphamide (AC) in
postoperative patients with breast cancer, reported that
additional treatment with paclitaxel was ineffective in
patients with ER-positive, HER2-negative tumors [18]. The
UK-based Taxotere as Adjuvant Chemotherapy Trial (UK-
TACT) studied the effect of adding docetaxel to FEC.
However, additional treatment with docetaxel was simi-
larly found to be ineffective in patients with ER-positive,
HER2-negative breast cancer [19].
ER-positive, HER2-negative breast cancer is thus less
sensitive to chemotherapy. In addition, there are no clear-
cut clinical guidelines for deciding whether a patient
should receive endocrine therapy alone or combined with
chemotherapy. Treatment selection is also complicated by
the fact that a patient’s diagnosis may be upgraded from
low risk to intermediate risk because of the presence of
only a single intermediate risk factor. Concern that addi-
tional postoperative chemotherapy may negatively affect
patients’ QOL by causing hair loss and other adverse
events also influences treatment decisions. Another
important factor is that intensive intravenous chemotherapy
is unsuitable for some patients because of advanced age,
concurrent disease, or other factors.
Recently, increasing emphasis has been placed on
assigning treatment policies according to the biologic
characteristics of tumors (molecular subtype), broadly
classified into 4 subtypes: luminal A, luminal B, triple-
negative, and HER2. Patients with triple-negative breast
cancer currently receive cytotoxic chemotherapy because
they lack distinct treatment targets. Drugs with various
molecular targets are currently being developed and are
Fig. 4 Relapse-free survival
according to estrogen receptor
(ER) and age in the pooled
analysis of NSAS-BC01 trial
and CUBC trial. HR hazard
ratio
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expected to improve treatment outcomes. The treatment of
HER2-positive breast cancer with trastuzumab, an anti-
HER2 agent, has considerably improved outcomes. Besides
trastuzumab, various types of drugs are scheduled to be
launched and are eagerly awaited.
Luminal A or B breast cancer is hormone sensitive and
treated by endocrine therapy. Chemotherapy is additionally
given to patients with a high baseline risk of recurrence.
Because luminal A breast cancer is considered to have
relatively low proliferative activity of tumor cells and low
sensitivity to conventional chemotherapy, endocrine ther-
apy is the mainstay of treatment. However, some patients
have a slightly increased baseline risk of recurrence. What
types of chemotherapeutic regimens should be additionally
given to such patients remains controversial. Luminal B
breast cancer is often associated with relatively high pro-
liferative activity and is frequently treated by chemother-
apy in addition to endocrine therapy. These two subtypes of
breast cancer are not only associated with early postoper-
ative recurrence, but also with late recurrence 5 or more
years after surgery.
The type of chemotherapy should be decided on the
basis of baseline risks and patients’ preferences. In Japan,
UFT has been shown to be noninferior to CMF in post-
menopausal women with hormone-sensitive breast cancer.
In contrast to conventional intravenous chemotherapy,
UFT is well tolerated and has become an important treat-
ment option supported by extensive evidence of efficacy.
UFT was developed in Japan. In particular, UFT differs
from other cytotoxic anticancer agents because UFT can be
used concurrently with endocrine therapy and can be
administered for a prolonged period. Experimental studies
have provided evidence that oral 5-FU is useful in com-
bination with tamoxifen. Concurrent use of 4-OH-tamoxi-
fen and 5-FU has been shown to have additive antitumor
activity [20]. As for the mechanism involved, tamoxifen
has been reported to lower the activity of TS, a key enzyme
in the inhibition of DNA synthesis by 5-FU, thereby
enhancing the antitumor activity of 5-FU. In studies
assessing the combined effectiveness of UFT and an aro-
matase inhibitor in cell lines with induced aromatase
expression, concurrent treatment with both drugs was
confirmed to significantly decrease tumor volume com-
pared to either drug alone [21].
Recent studies of chemotherapy combined with endo-
crine therapy have reported that aromatase-inhibitor-based
endocrine therapy plus chemotherapy is useful [22, 23]. In
addition, GHB and GBL derived from tetrahydrofuran
metabolites specific to tegafur have been shown to inhibit
angiogenesis. Therefore, long-term, metronomic treatment
with UFT may produce high antitumor activity [24]. Long-
term treatment with UFT may continuously inhibit tumor
angiogenesis, suppressing postoperative metastasis.
Although evidence derived from clinical studies sup-
porting the combined use of UFT and an aromatase
inhibitor is currently unavailable, these drugs are often
combined in clinical practice. In a survey primarily
designed to confirm the tolerability of 1-year postoperative
treatment with UFT [25], UFT was given from 2002
through 2005. Among 1,995 patients in whom safety was
assessable at 1 year, 273 concurrently received UFT plus
anastrozole, 398 received UFT alone, and 127 received
UFT plus tamoxifen. Treatment in these 3 groups was
confirmed to be safe and adequately tolerable. As men-
tioned above, experimental studies have shown that con-
current treatment with UFT and anastrozole results in
higher antitumor activity than either UFT or anastrozole
alone. On the basis of available evidence, combined use of
UFT plus an aromatase inhibitor is thus considered a viable
option for postoperative adjuvant chemotherapy in addition
to the evidence-based combination of UFT plus tamoxifen.
Other oral 5-FU derivatives studied as postoperative
chemotherapy include capecitabine and doxifluridine, a
metabolite of capecitabine. Like UFT, doxifluridine has
been mainly evaluated as postoperative chemotherapy in
Japan; however, its usefulness as compared with surgery
alone could not be demonstrated [26]. The CALGB/CTSU
49907 trial compared capecitabine, a more tumor-selective
drug than doxifluridine, with standard control treatment
comprising CMF or AC in older patients with breast can-
cer. Capecitabine was not demonstrated to be therapeuti-
cally useful compared with standard treatment [27].
However, that study also showed an interaction between
hormone-receptor status and treatment response, suggest-
ing a relation between the response to oral 5-FU and hor-
mone receptors. Several reasons may explain why these
drugs were not shown to be useful for postoperative che-
motherapy in breast cancer. First, the treatment period was
short (duration of treatment with UFT in clinical trials,
about 2 years), and the study protocols differed with
respect to the timing of endocrine therapy (tamoxifen
concurrently used in all clinical trials of UFT). Second,
doxifluridine and capecitabine are activated by thymidylate
phosphorylase in tumors and therefore might not be ade-
quately effective in a postoperative environment associated
with only micrometastases and virtually no tumor.
As mentioned above, clinical studies of UFT, an oral 5-FU
derivative, have been performed in Japan and suggested that
concurrent use of tamoxifen or an aromatase inhibitor is
therapeutically useful. Such therapy may become a treatment
option for patients who have ER-positive, HER2-negative
luminal breast cancer with intermediate or high baseline
risks. In particular, UFT is associated with few adverse
events and a good QOL, making it an important option
for optimal treatment prescribed according to patients’
preferences.
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When antitumor activity against MCF-7/Arom 14 cells
was compared among S-1, anastrozole, and S-1 plus an-
astrozole, S-1 plus anastrozole was confirmed to have
significantly higher antitumor activity than either S-1 or
anastrozole alone [28].
S-1 combined with standard postoperative endocrine
therapy may further enhance inhibition of recurrence in
patients with ER-positive, HER2-negative primary breast
cancer. The POTENT study is ongoing. This study is being
performed in patients with an intermediate risk of recur-
rence for whom standard chemotherapy was not clearly
indicated, as well as patients with a high risk of recurrence
in whom standard chemotherapy was indicated. In this
study, whether to administer standard adjuvant chemo-
therapy as prior treatment is left to the physicians’ dis-
cretion. When the results of this study become available, it
will be possible to study the relation between standard
chemotherapy given as prior treatment, and the effective-
ness of S-1 for preventing recurrence. Regardless of whe-
ther the addition of current standard chemotherapy to
endocrine therapy is supported or not supported by the
results of other ongoing clinical trials, the results of these
studies are expected to be highly applicable to clinical
practice.
S-1 is an oral drug with a relatively low incidence of
adverse events, allowing treatment without compromising
patients’ QOL. As compared with new drugs such as
molecular targeted agents, S-1 is less expensive and may
thus be a cost-effective treatment for breast cancer.
In summary, UFT and other oral preparations of 5-FU
were previously used without adequate evidence of effec-
tiveness, but their use is now internationally supported by
the results of a series of controlled clinical trials supporting
the benefits and safety of these agents for the management
of breast cancer. The results of the POTENT trial are
awaited.
Conflict of interest I am an advisor to TAIHO Pharmaceutical Co.,
Ltd. The remuneration is 2,400,000 yen.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B,
Senn HJ. Thresholds for therapies: highlights of the St Gallen
International Expert Consensus on the primary therapy of early
breast cancer 2009. Ann Oncol. 2009;20:1319–29.
2. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D,
Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new
class of tumour-inhibitory compounds. Nature. 1957;179:663–6.
3. Kasumi F, Yoshimoto M, Uchino J, Abe R, Nomura Y, Sugi-
machi K, et al. Meta-analysis of five studies on tegafur plus uracil
(UFT) as post-operative adjuvant chemotherapy for breast cancer.
Oncology. 2003;64:146–53.
4. Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K,
et al. Postoperative adjuvant therapy with tamoxifen, tegafur plus
uracil, or both in women with node-negative breast cancer: a
pooled analysis of six randomized controlled trials. J Clin Oncol.
2005;23:2172–84.
5. Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y,
Yoshimoto M, et al. Oral uracil and tegafur compared with
classic cyclophosphamide, methotrexate, fluorouracil as postop-
erative chemotherapy in patients with node-negative, high-risk
breast cancer: National Surgical Adjuvant Study for Breast
Cancer 01 Trial. J Clin Oncol. 2009;27:1368–74.
6. Park Y, Okamura K, Mitsuyama S, Saito T, Koh J, Kyono S, et al.
Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrex-
ate, fluorouracil, and tamoxifen in post-operative adjuvant ther-
apy for stage I, II, or IIIA lymph node-positive breast cancer: a
comparative study. Br J Cancer. 2009;101:598–604.
7. Takatsuka Y, Park Y, Okamura K, Mitsuyama S, Saito T, Koh J,
et al. Relationship between estrogen receptor (ER) status and
efficacy of postoperative adjuvant chemotherapy with oral tega-
fur-uracil (UFT) or CMF: subset analysis from a randomized
controlled trial (CUBC trial in Japan). EJC Suppl. 2008;6:117–8.
8. Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K,
Hashimoto A, et al. gamma-Hydroxybutyric acid and 5-fluoro-
uracil, metabolites of UFT, inhibit the angiogenesis induced
by vascular endothelial growth factor. Angiogenesis. 2001;4:
163–73.
9. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A,
Miyadera K, et al. UFT and its metabolites inhibit the angio-
genesis induced by murine renal cell carcinoma, as determined by
a dorsal air sac assay in mice. Clin Cancer Res. 1999;5:2185–91.
10. Toi M, Ikeda T, Akiyama F, Kurosumi M, Tsuda H, Sakamoto G,
et al. Predictive implications of nucleoside metabolizing enzymes
in premenopausal women with node-positive primary breast
cancer who were randomly assigned to receive tamoxifen alone
or tamoxifen plus tegafur-uracil as adjuvant therapy. Int J Oncol.
2007;31:899–906.
11. Ohashi Y, Watanabe T, Sano M, Koyama H, Inaji H, Suzuki T.
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as
compared with classical cyclophosphamide, methotrexate, and
5-fluorouracil (CMF) in early breast cancer: a pooled analysis of
two randomized controlled trials (N.SAS-BC 01 trial and CUBC
trial). Breast Cancer Res Treat. 2010;119:633–41.
12. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects
of pyrimidine, barbituric acid and pyridine derivatives on 5-flu-
orouracil degradation in rat liver extracts. Jpn J Cancer Res.
1987;78:748–55.
13. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S,
et al. A phase II study of S-1 in patients with metastatic breast
cancer—a Japanese trial by the S-1 Cooperative Study Group.
Breast Cancer Working Group. Breast Cancer. 2004;11:
194–202.
14. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data
and cohort investigation in UFT phase II study. Cancer Chemo-
ther Pharmacol. 1988;22:333–8.
15. Hortobagyi GN, Heim W, Hutchins L, Rivera E, Mason B,
Booser DJ, et al. A phase 2 study of a fixed combination of uracil
and ftorafur (UFT) and leucovorin given orally in a 3-times-daily
regimen to treat patients with recurrent metastatic breast cancer.
Cancer. 2010;116:1440–5.
16. Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R,
Murray JL, et al. A phase 2 study of a fixed combination of uracil
and ftorafur and leucovorin given orally in a twice-daily regimen
308 Breast Cancer (2013) 20:302–309
123
to treat patients with recurrent metastatic breast cancer. Cancer.
2010;116:2301–6.
17. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M,
Pfeffer U, et al. HER2 status and efficacy of adjuvant anthracy-
clines in early breast cancer: a pooled analysis of randomized
trials. J Natl Cancer Inst. 2008;100:14–20.
18. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan
D, et al. HER2 and response to paclitaxel in node-positive breast
cancer. N Engl J Med. 2007;357:1496–506.
19. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A,
O’Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy
for early breast cancer (TACT): an open-label, phase III, ran-
domised controlled trial. Lancet. 2009;373:1681–92.
20. Kurebayashi J, Nukatsuka M, Nagase H, Nomura T, Hirono M,
Yamamoto Y, et al. Additive antitumor effect of concurrent
treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with
doxorubicin in estrogen receptor-positive breast cancer cells.
Cancer Chemother Pharmacol. 2007;59:515–25.
21. Kurebayashi J, Nukatsuka M, Sonoo H, Uchida J, Kiniwa M.
Preclinical rationale for combined use of endocrine therapy and
5-fluorouracil but neither doxorubicin nor paclitaxel in the
treatment of endocrine-responsive breast cancer. Cancer Che-
mother Pharmacol. 2010;65:219–25.
22. Chen D, Hackl W, Ortmann O, Treeck O. Effects of a combi-
nation of exemestane and paclitaxel on human tumor cells
in vitro. Anticancer Drugs. 2004;15:55–61.
23. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S,
et al. Randomized phase II trial of letrozole and letrozole plus
low-dose metronomic oral cyclophosphamide as primary sys-
temic treatment in elderly breast cancer patients. J Clin Oncol.
2006;24:3623–8.
24. Uchida J, Okabe H, Nakano K, Fujioka A, Saito H, Sugimoto Y,
et al. Contrasting effects of extended low dose versus standard
dose shorter course UFT chemotherapy on microscopic versus
macroscopic established tumors: implications for optimal post-
operative adjuvant chemotherapy. Oncol Rep. 2007;18:313–9.
25. Taguchi T, Noguchi S. Safety and compliance with UFT (tegafur and
uracil) alone and in combination with hormone therapy in patients
with breast cancer. Gan To Kagaku Ryoho. 2009;36:1465–74.
26. Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H,
et al. The effect of adjuvant 50-deoxy-5-fluorouridine in early
stage breast cancer patients: results from a multicenter random-
ized controlled trial. Int J Oncol. 2002;20:517–25.
27. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM,
Kornblith AB, et al. Adjuvant chemotherapy in older women with
early-stage breast cancer. N Engl J Med. 2009;360:2055-65.
28. Nukatsuka M, Saito H, Nakagawa F, Abe M, Uchida J, Shibata J,
et al. Oral fluoropyrimidine may augment the efficacy of aro-
matase inhibitor via the down-regulation of estrogen receptor in
estrogen-responsive breast cancer xenografts. Breast Cancer Res
Treat. 2011;128:381–90.
Breast Cancer (2013) 20:302–309 309
123
